Amblyopia Eye Patches in Canada vs the US: Which Patching Rules Apply?

Quick facts

• Amblyopia is a cortical outcome, not an eye problem. Reduced acuity in one eye persists after refractive correction because the visual pathway did not develop normally; occlusion of the better-seeing eye and atropine penalisation are the two first-line routes, and both are prescribed, not self-selected.
• The United States classifies the devices by function. The Food and Drug Administration lists eye shields under 21 CFR 886.4750 as Class I (general controls), and created a separate Class II entry, 21 CFR 886.5500, for digital therapy devices that treat amblyopia through dichoptic presentation.
• Canada classifies by risk, not by name. There is no Canadian entry for an eye patch as such; the class follows the rules in the Medical Devices Regulations (SOR/98-282), and a Canadian importer or distributor of a Class I device still needs an establishment licence rather than a device licence.
• Screening finds the child. The US Preventive Services Task Force recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factors; in Canada the vision items sit inside scheduled well-child visits in the Rourke Baby Record.
• Who pays changes who turns up. Ontario's OHIP covers a full eye exam for children with a valid health card, so the examination that finds amblyopia is insured for that age group — a different financing route from the United States.
• The hours are the therapy. Patching is dosed in hours per day and reviewed on a schedule, so the occlusion hours recorded in the chart are part of the treatment, not an administrative detail.

An amblyopia eye patch is one of the few clinical consumables where the product itself is simple and everything that determines the outcome sits outside the product: the screening that found the child, the prescription that set the dose, the anatomy the patch has to sit on, and the follow-up that decides when to stop.

That shape makes it a good subject for a buyer's comparison, because the two countries solve the same clinical problem through different regulatory and funding routes. This article sets out what occlusive patching is, how Canada and the United States each classify the device, how a child reaches patching in each system, which patch formats a clinic stocks, and what the record has to contain.

What is an amblyopia eye patch, and when is occlusion therapy used?

Occlusion therapy works by removing the input from the better-seeing eye so the amblyopic eye is forced to take over. The patch is therefore an occluder — it does not treat the eye it covers, and that is a common misunderstanding.

The clinical sequence is fixed:

1. Refraction first. Glasses are prescribed and worn before patching is judged to have failed, because part of the acuity deficit in many children is refractive and resolves with correction alone.
2. Dose second. Occlusion is prescribed in hours per day, banded by age and severity, and reviewed rather than fixed for the duration.
3. Alternative where occlusion fails. Atropine penalisation blurs the better-seeing eye instead of covering it, and is used where a child will not tolerate an adhesive patch or where the skin reacts.

Two practical consequences follow for a clinic. First, the patch has to stay in place during waking activity, which makes adhesion and skin tolerance a clinical variable and not a comfort feature. Second, because the treatment runs for months, a clinic that patches children routinely goes through a steady volume of single-use patches, tape and skin-preparation supplies rather than a one-off purchase.

How do Canada and the US regulate the patch itself?

This is where the two systems diverge, and the divergence is about how a regulator files a device rather than about whether the patch is safe.

The United States works from named entries. The Food and Drug Administration classifies an ophthalmic eye shield — "a plastic or aluminum eye covering intended to protect the eye or retain dressing materials in place" — as Class I (general controls) under 21 CFR 886.4750, exempt from premarket notification when made only of plastic or aluminum, subject to 21 CFR 886.9. Occlusion that delivers therapy through software sits in a different entry altogether: 21 CFR 886.5500 describes a device that "incorporates dichoptic presentations on visual displays through therapeutic algorithms to treat amblyopia or to improve visual acuity of patients with amblyopia", and places it in Class II (special controls) with clinical performance testing, software verification and validation, and hazard analysis as the special controls.

Canada works from risk classes. The Medical Devices Regulations do not name an eye patch; the device is assigned to Class I to IV by the rules in the regulations, and the licensing obligation follows the class. A Class I device does not require a device licence, but the manufacturer, importer and distributor still sit inside the establishment licensing regime — which is why the practical question for a Canadian buyer is not "does the patch have a licence number" but "does the establishment that puts it into Canada hold an establishment licence".

That difference is the fact worth remembering from this section: the US answer is a named entry and a class, and the Canadian answer is a derived class and an establishment licence.

Item	Canada	United States
Named entry for an eye patch	None; class is derived from the rules	21 CFR 886.4750, ophthalmic eye shield
Named entry for software-driven occlusion	None; class is derived from the rules	21 CFR 886.5500, digital therapy device for amblyopia
Class of the protective occluder	Derived (Class I to IV by rule)	Class I (general controls)
Class of digital amblyopia therapy	Derived (Class I to IV by rule)	Class II (special controls)
Premarket position of a plastic or aluminium shield	Device licence where the derived class requires it	Exempt from premarket notification, subject to § 886.9
Establishments that bring the product to market	Establishment licence for manufacturer, importer and distributor	Establishment registration and device listing
Who prescribes the occlusion	The treating optometrist or ophthalmologist	The treating optometrist or ophthalmologist

How does screening reach a child before patching starts?

Patching only helps children who are found, and the two countries find them at different points in the system.

In the United States, the entry point is a graded population recommendation. The US Preventive Services Task Force recommends vision screening at least once in all children aged 3 to 5 years "to detect amblyopia or its risk factors", which is a recommendation addressed to primary care rather than to eye care. In practice the screen happens in a paediatric or family practice visit, and a failed screen is referred out.

In Canada, the same function is carried inside scheduled well-child care. The Rourke Baby Record, which is the record Canadian primary care uses for infant and child visits, includes vision items at defined visits, so the child is reviewed repeatedly rather than screened once. Provincial and school-based screening sit alongside it where they operate.

The funding layer then decides who can act on the finding. Ontario's OHIP schedule covers a full eye examination for children with a valid health card, and the College of Optometrists of Ontario sets out the funding options that apply to examinations in the province. In the United States, coverage for a paediatric eye examination depends on the plan.

Item	Canada	United States
Where the first vision screen happens	Scheduled well-child visits, plus provincial and school programmes	Primary care visit; task force recommendation
Population guidance	Vision items built into the well-child record	Vision screening at least once, ages 3 to 5 years
Body issuing the guidance	Canadian paediatric primary care record	US Preventive Services Task Force
Public funding of the diagnostic exam	Insured for children under the provincial health plan	Plan-dependent
Referral route after a failed screen	Family physician or paediatrician to optometry or ophthalmology	Primary care to optometry or ophthalmology

Which patch formats and accessories does a clinic stock?

Because the prescription sets the hours and the parent administers them, the clinic's stock decision is about what survives on a child's face for the prescribed window.

Format	What it is	Typical clinic use
Adhesive single-use occlusive patch	A shaped adhesive patch applied directly over the closed eyelid	The usual first-line route where skin tolerance allows
Reusable fabric occluder over glasses	A fabric cover that blocks the lens of the better eye	Children who react to adhesive, or where a removable cover is preferred
Eye shield plus tape	A rigid shield or a gauze pad retained with tape	Where the eye has to be protected rather than simply covered
Atropine drops	Pharmacological penalisation instead of occlusion	Documented alternative when patching is not tolerated
Skin preparation and removal supplies	Cleansing wipes and low-irritation tape	Reducing adhesive reactions during a long course

Two stock items do the quiet work in this list. A sterile gauze pad and a roll of hypoallergenic tape are what turn a rigid shield into a workable dressing when a child has a concurrent eye injury, and both are consumed at every visit that involves a dressing change. CliniEco Medical stocks sterile gauze sponges and paper hypoallergenic tape for paediatric dressing and lane supplies, alongside the exam table paper and disposable tongue depressors that paediatric lanes use between patients.

What should the chart record once patching starts?

The record is what makes a course of patching auditable and what allows the prescriber to change the dose on evidence rather than on impressions. In both countries the same five items carry the course:

• The prescription. Hours per day, which eye is occluded, and the date the dose was set.
• The refracted acuity of each eye at the start of occlusion, with the method used to measure it — the acuity chart itself is a classified device in the United States under 21 CFR 886.1150, and the same chart is what makes the starting point comparable later.
• Adherence and tolerance. How many hours were actually worn, and any skin reaction that forced a change of format.
• The review interval and outcome. Vision at each review, and the decision to continue, change the dose, or switch to penalisation.
• The products dispensed, so that the supply chain can be matched to the course length.

For a clinic that buys in bulk, that last item is what connects the clinical record to procurement, because a fixed weekly patch count over a defined course produces a predictable consumable draw.

Sources

1. 21 CFR 886.5500, digital therapy device for amblyopia
2. 21 CFR 886.4750, ophthalmic eye shield
3. 21 CFR 886.1150, visual acuity chart
4. 21 CFR 886.9, limitations of exemptions from section 510(k)
5. 21 CFR 886.1290, binocular vision training fixation device
6. American Academy of Ophthalmology, amblyopia
7. American Academy of Ophthalmology, patching therapy
8. American Academy of Ophthalmology, children's vision development
9. American Association for Pediatric Ophthalmology and Strabismus, amblyopia
10. American Association for Pediatric Ophthalmology and Strabismus, vision screening
11. American Optometric Association, amblyopia
12. HealthyChildren.org, eye conditions
13. US Preventive Services Task Force, vision in children ages 6 months to 5 years
14. Rourke Baby Record, interactive guide
15. Rourke Baby Record, downloads
16. Canadian Association of Optometrists, amblyopia
17. Canadian Association of Optometrists, eye health library
18. Ontario, what OHIP covers
19. College of Optometrists of Ontario, funding options for eye examinations
20. Medical Devices Regulations, SOR/98-282
21. ISO 15004-1:2020, ophthalmic instruments, fundamental requirements
22. World Health Organization, blindness and visual impairment

Ordering for a clinic, optometry group or paediatric lane? Wholesale and multi-site ordering covers account setup and case pricing, and the B2B wholesale collection lists the lines stocked for institutional buyers. Clinics that also hold an in-house sterilizer for reusable instruments can start with the biological indicator 5-pack trial, and the sterilization monitoring collection lists the monitoring lines.

Related reading

• Eye patches in Canada vs the US: which types and coverage routes apply
• Eye tests for preschoolers in Canada vs the US: which screening rules apply
• Comprehensive eye check-ups in Canada vs the US: which exam interval applies
• Eye clinic consumables: gloves, swabs and tape for optometry

Frequently Asked Questions

Is an amblyopia eye patch a licensed device in Canada?

There is no Canadian entry that names an eye patch. The device takes the class assigned to it by the rules in the Medical Devices Regulations, and the obligation that follows depends on that class: a Class I device does not need a device licence, while a Canadian manufacturer, importer or distributor still operates under the establishment licensing regime. The practical check for a buyer is the establishment that places the product on the Canadian market, not a licence number printed on a patch.

Does the FDA have a specific entry for occlusion patches?

The FDA classification database lists an ophthalmic eye shield under 21 CFR 886.4750 as a Class I device, describing a plastic or aluminium covering intended to protect the eye or hold dressing material in place. Occlusion delivered by software is filed separately: 21 CFR 886.5500 covers a digital therapy device for amblyopia with dichoptic presentations and places it in Class II with special controls. The two entries explain why the same clinical goal produces two different filing routes.

How are children found before patching is prescribed?

In the United States the US Preventive Services Task Force recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factors, which puts the first test in a primary care visit. In Canada the vision items are built into the scheduled well-child record used by primary care, so the child is reviewed at defined visits rather than screened once, with provincial and school programmes adding further checks.

What should a clinic record during a course of patching?

Five items carry the course: the prescription in hours per day and the occluded eye, the refracted acuity of each eye at the start, the hours actually worn together with any skin reaction that changed the format, the review interval with the outcome at each visit, and the products dispensed. The last item links the clinical record to procurement.

Is patching the only treatment for amblyopia?

No. Occlusion of the better-seeing eye and atropine penalisation are the two established first-line routes, and the choice between them turns on the age of the child, the depth of the deficit, and whether the child tolerates an adhesive patch. Refractive correction is prescribed and worn before either route is judged to have failed.

Which supplies does patching consume in a clinic?

Two groups. The occlusion supplies themselves — single-use adhesive patches, reusable fabric occluders for glasses, or a rigid shield with a gauze pad and tape where the eye also has to be protected — and the lane supplies consumed at each review, including exam table paper, gloves, and the low-irritation tape and cleansing wipes that manage adhesive reactions.

CliniEco Medical supplies clinic, optometry and laboratory consumables of the kind described in this article. Health Canada MDEL #35334. This article is written for clinic, optometry and procurement professionals and is not clinical guidance; the decision to patch, the dose, and the review schedule belong to the treating optometrist or ophthalmologist.